TITLE
Clinical Integration of CELMoDs in Multiple Myeloma Care

PROGRAM PARTNERS
This activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical and RealCME

ACKNOWLEDGEMENT OF FINANCIAL SUPPORT
This activity is supported by an educational grant from Bristol Meyers Squibb

Release Date: June 11, 2026

Expiration Date: June 11, 2027

STATEMENT OF NEED
The rapid evolution of multiple myeloma (MM) treatment has introduced cereblon E3 ligase modulators (CELMoDs), a next-generation class of oral therapies designed to overcome the limitations of traditional immunomodulatory drugs (IMiDs). Despite their promise in relapsed/refractory and frontline settings, significant educational gaps persist regarding their distinct biologic mechanisms, optimal sequencing within complex treatment paradigms—particularly alongside CAR-T and bispecific antibodies—and the recognition of class-specific toxicities. As late-phase data mature and regulatory approvals approach, community-based practitioners face the challenge of integrating these "off-the-shelf" agents into routine practice without the specialized infrastructure of academic centers. Improved clinician understanding of enhanced cereblon engagement and deeper protein degradation is essential to prevent CELMoDs from being viewed as interchangeable with older agents, ensuring informed decision-making and the maintenance of treatment continuity through proactive supportive care.

To address these challenges, this educational initiative utilizes an expert-led, longitudinal small-group model designed to immerse community-based hematologists/oncologists, nurses, and pharmacists in collaborative peer learning. By fostering a sustainable network of multidisciplinary clinicians, the program facilitates the exchange of real-world approaches and strategies for managing CELMoD-associated adverse events, such as myelosuppression and infection risk.

EDUCATIONAL OBJECTIVES

1. DESCRIBE the mechanism of action of cereblon E3 ligase modulators (CELMoDs) and their biologic and immune effects in MM
2. EXPLAIN how CELMoDs differ biologically and clinically from traditional IMiDs
3. ANALYZE emerging clinical scenarios in RRMM to inform potential sequencing and integration considerations for CELMoDs
4. IDENTIFY safety considerations associated with novel CELMoD therapies, including adverse event recognition and management in RRMM

TARGET AUDIENCE
Hematologists/oncologists, nurses, advance practice providers (NPs, PAs), and pharmacists who treat multiple myeloma with a focus on community practitioners

FACULTY

CONTENT REVIEWER

David M. Kaufman, MD

Professor of Neurology and Psychiatry

Albert Einstein College of Medicine

Montefiore Medical Center

Bronx, NY

Has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.

PLANNERS

Steven Haimowitz, MD
RealCME

Steven Haimowitz, MD, has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.

Technical Writer:

Erika L Kunz, PharmD

Erika L Kunz, PharmD, has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.

DISCLOSURE OF FINANCIAL RELATIONSHIPS
The “Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that any individual in control of content, including faculty, participating in CME activities disclose to the audience all relevant financial relationships with ineligible companies* in the past 24 months. Any individual in control of content who refuses to disclose, or whose disclosed relationships prove to create a conflict of interest, will be recused.

Individuals with the absence of relevant financial relationships with ineligible companies will be disclosed to the audience.

All financial relationships of individuals in a position to control the content of this CME activity are identified and mitigated prior to the educational activity.

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PROVIDERSHIP

This educational activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center, the Obesity Medicine Association and RealCME.  

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME, LLC. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center designates this other/blended activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Program

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE OF UNLABELED USE
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient’s medical condition.

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine-Montefiore Medical Center, RealCME, and Bristol Meyers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

METHOD OF PARTICIPATION/INSTRUCTIONS ON HOW TO RECEIVE CREDIT

Estimated time to complete this activity:  4.75 hours

To obtain credit, a score of 70% or better on the Final Assessment is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this curriculum, answered all test questions, completed the Final Assessment, Post Group Assessment, and evaluation, and have received a digital copy of your credit certificate.

• Baseline/Final Assessments: 30 minutes each for a total of up to 1.00 hour of CME
• Three (3) Self-Study Modules: 15 minutes each for a total of up to 0.75 hour of CME
• Two (2) Live Group Discussions: 45 minutes each for a total of up to 1.50 hour of CME
• Two (2) Group Challenges: 30 minutes each for a total of up to 1.00 hour of CME
• Action Plan (1) development: 30 minutes for a total of 0.50 hour of CME

If you are seeking credit, you must complete the assessment and evaluation at the conclusion of the activity. Your certificate can be printed immediately.


PRIVACY STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and education collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME. Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.

COLLECTION AND USE OF YOUR PERSONAL INFORMATION
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, middle initial, degree, email address, address and phone number. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Einstein-Montefiore to continuously improve the learning experience. Einstein-Montefiore will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Einstein-Montefiore will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

CONTACT INFORMATION
For questions regarding CME credit, contact Albert Einstein College of Medicine-Montefiore Medical Center at cme@montefiore.org.

For technical questions related to this activity, please contact support@gathered.com.